Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Biotinylated Human LILRB3 / CD85a / ILT5 Protein, Fc,Avitag™, 25 µg  

Recombinant Biotinylated Human LILRB3 / CD85a / ILT5 Protein, Fc,Avitag™, 25 µg

Recombinant Biotinylated Human LILRB3 / CD85a / ILT5 Protein, AA Gly 24 - Glu 443, expressed from human 293 cells (HEK293), Fc,Avitag™ (MALS verified)

Synonym: Recombinant, LILRB3, CD85a, ILT5

More details

CDA-H82F6-25

Availability: within 7 days

455,00 €

Background
Leukocyte immunoglobulin-like receptor subfamily B member 3 is also known as LILRB3,ILT-5 or CD85a. LILRB3 plays an role as receptor for class I MHC antigens, which activated upon coligation of LILRB3 and immune receptors, such as FCGR2B and the B-cell receptor. LILRB3 and LILRA6 represent a pair of inhibitory/activating receptors with identical extracellular domains and unknown ligands. LILRB3 can mediate inhibitory signaling via immunoreceptor tyrosine-based inhibition motifs in its cytoplasmic tail whereas LILRA6 can signal through association with an activating adaptor molecule, FcRγ.

Source
Recombinant Biotinylated Human LILRB3, Fc,Avitag (CDA-H82F6) is expressed from human 293 cells (HEK293). It contains AA Gly 24 - Glu 443 (Accession # AAI12199).
Predicted N-terminus: Gly 24

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 74.6 kDa. As a result of glycosylation, the protein migrates as 80-105 kDa under reducing (R) condition, and 150 kDa under non-reducing (NR) condition (SDS-PAGE).

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
Biotin:Protein Ratio
Passed as determined by the HABA assay / binding ELISA.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Clinical and Translational Updates

(1)  "LILRB3 supports immunosuppressive activity of myeloid cells and tumor development"
Huang, Liu, Kim et al
Cancer Immunol Res (2023)
(2)  "LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy"
Mai, Hodges, Chen et al
Cancer Res (2023) 83 (24), 4047-4062
(3)  "Omic horizon expression: a database of gene expression based on RNA sequencing data"
Hu, Xie, Li et al
BMC Genomics (2023) 24 (1), 674
Showing 1-3 of 54 papers.

The following products could also be interesting for you: